Terapie modyfikujące przebieg choroby w rozwoju dla padaczki pourazowej
Disease-modifying therapies in development for post-traumatic epilepsy
W skrócie
Padaczka pourazowa to trwała choroba neurologiczna, która pojawia się po urazie mózgu i stanowi 20% wszystkich nabytych padaczek. Dotychczasowe leki przeciwpadaczkowe tylko zmniejszają napady, ale nie zapobiegają rozwojowi choroby i nie poprawiają długoterminowych problemów neurologicznych. Badanie omawia nowe obiecujące podejścia terapeutyczne, takie jak modulatory epigenetyczne, leki przeciwzapalne i inne, które mogą zarówno zapobiec rozwojowi padaczki, jak i poprawić wyniki zdrowotne pacjentów po urazie mózgu.
Oryginalny abstract (angielski)
Post-traumatic epilepsy (PTE) is a chronic neurological disorder that develops following traumatic brain injury (TBI), a condition affecting nearly 69 million people worldwide. PTE accounts for 20% of acquired epilepsies and is characterized by spontaneous recurrent seizures and long-term neurological deficits. Current antiseizure medications primarily suppress early seizures but do not prevent epileptogenesis or improve neurological dysfunction. This review critically evaluates the current landscape of disease-modifying therapies for PTE with an emphasis on pathophysiological basis, therapeutic pipeline and challenges in developing antiepileptogenic drugs for preventing PTE and improving long-term neurological outcomes after TBI. Epileptogenesis following TBI is driven by dynamic interactions among neuronal, glial, vascular, immune, metabolic, and epigenetic pathways that evolve from the acute injury phase through the latent period to chronic epilepsy. Consequently, therapeutic interventions differ in optimal timing and target objectives of acute neuroprotection, prevention of epileptogenesis, or modification of established epilepsy and its comorbidities. Promising disease-modifying approaches include epigenetic modulators, anti-inflammatory & immunomodulatory agents, JAK-STAT inhibitors, mTOR inhibitors, antioxidant & mitochondrial-targeted therapies, tau-directed interventions, adenosine augmentation, neurosteroids, and regenerative cell-based therapies. Among these, epigenetic therapy targeting histone deacetylases has emerged as a particularly attractive strategy. Pharmacological inhibition of histone deacetylase has demonstrated robust disease-modifying effects in experimental PTE by normalizing aberrant histone deacetylase activity, suppressing neuroinflammation, reducing seizure burden, and attenuating biomarkers of epileptogenic progression. Despite multiple approaches in development, no therapy has yet demonstrated clinical efficacy for preventing human PTE. Major translation barriers include the heterogeneity of PTE, limitations of experimental models, inconsistent biomarker validation, and challenges in clinical studies. Future progress will require standardized paradigms, rigorous preclinical evaluation, biomarker-guided clinical trials, and optimization of disease-modifying therapies capable of preventing epilepsy and improving long-term neurological outcomes after brain injury.